0.00Open0.00Pre Close0 Volume0 Open Interest1.00Strike Price0.00Turnover324.96%IV-46.24%PremiumJul 19, 2024Expiry Date0.86Intrinsic Value100Multiplier12DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9084Delta0.1462Gamma2.01Leverage Ratio-0.0074Theta0.0003Rho1.83Eff Leverage0.0006Vega
Standard BioTools Stock Discussion
assay services, kits and related revenue in 2024; and
-- Ended the quarter with cash, cash equivalents, restricted cash and
short-term investments of $464 million, after accounting for $71 million
cash payments for merger-related expenses, settlement of year-end
operating accruals, debt retirement and completed stock buybacks.
2 MINUTES AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE
Benzinga· 1 min ago
No comment yet